Although hypomethylation was the originally identified epigenetic change in cancer, it was overlooked for many years in preference to hypermethylation. Recently, gene activation by cancer-linked hypomethylation has been rediscovered. However, in gastric cancer, genome-wide screening of the activated genes has not been found. By using microarrays, we identified 1,383 gene candidates reactivated in at least one cell line of eight gastric cancer cell lines after treatment with 5-aza-2Vdeoxycytidine and trichostatin A. Of the 1,383 genes, 159 genes, including oncogenes ELK1, FRAT2, R-RAS, RHOB, and RHO6, were further selected as gene candidates that are silenced by DNA methylation in normal stomach mucosa but are activated by DNA demethylation in a subset of gastric cancers. Next, we showed that demethylation of specific CpG sites within the first intron of R-RAS causes activation in more than half of gastric cancers. Introduction of siRNA into R-RAS-expressing cells resulted in the disappearance of the adhered cells, suggesting that functional blocking of the R-RAS-signaling pathway has great potential for gastric cancer therapy. Our extensive gene list provides other candidates for this class of oncogene. (Cancer Res 2005; 65(6): 2115-24) 
Introduction
DNA hypermethylation in cancer has been observed most often in CpG islands in gene regions and leads to down-regulation of tumor suppressor genes (1, 2) . Recently, histone modifications and silencing before DNA methylation of the p16/INK4A gene has been reported (3) . Therefore, whether DNA hypermethylation is a cause of tumorigenesis remains unestablished. In contrast, very frequent hypomethylation is seen in both highly and moderately repeated DNA sequences in many human cancers, including heterochromatic DNA repeats, dispersed retrotransposons, and endogenous retroviral elements (4) . Whether genome-wide DNA hypomethylation, however, is a cause or consequence of tumorigenesis has been unclear. As possible mechanisms, insertional activation of protooncogenes by induction of endogenous retroviral elements (5) and induction of genomic instability (6) were previously considered. Recently, mutant mice carrying a hypomorphic DNA methyltransferase 1 (Dnmt 1) have been reported to develop aggressive T-cell lymphomas that displayed a high frequency of chromosome 15 trisomy (7) . This article shows that DNA hypomethylation plays a causal role in tumor formation, possibly by promoting chromosomal instability. For gene activation by cancer-linked hypomethylation, in 1983 Feinberg and Vogelstein (8) first reported that human growth hormone, a-globin, and h-globin are methylated in normal tissues and become hypomethylated in cancers. It has been rediscovered recently that the cancer-linked hypomethylation leads to activation of genes that are important in cancer (4) . A correlation between hypomethylation and overexpression has been shown for MN/CA9 encoding a tumor antigen in renal cell carcinomas (9) , MDR1 in myeloid leukemias (10) , BCL-2 in chronic lymphocytic leukemias (11) , MAGE-1 in melanomas (12) , and SNCG/BCSG1 in breast carcinomas and ovarian carcinomas (13) . SNCG, also referred to as BCSG1, is a member of a neuronal protein family, synuclein, and its expression is highly tissue-specific (14, 15). As described above, it was clearly shown that hypomethylation of the SNCG gene CpG island promotes its aberrant expression in breast and ovarian carcinomas (13) . Extensive recent study of pancreatic cancer by microarray analysis showed that frequent hypomethylation of seven genes (claudin4, lipocalin2, 14-3-3r, trefoil facter2, S100A4, mesothelin, and prostate stem cell antigen) caused overexpression (16) . In the early studies, c-MYC, H-RAS, c-FOS, and AFP genes have been reported to be less hypomethylated in gastric cancer tissues than in noncancerous tissues (17) . However, in gastric cancer, genome-wide screening of the activated genes has not been found. In this study, using genome-wide expression analysis, we screened genes activated by cancer-linked hypomethylation in gastric cancer.
Materials and Methods
Tissue Samples and 5-Aza-2VDeoxycytidine and Trichostatin A Treatment of Gastric Cancer Cells. Thirty-three gastric cancer tissues and six noncancerous tissues were obtained with informed consent from patients who underwent a gastrectomy at the National Cancer Center Hospital (Tokyo, Japan). Eight cell lines (HSC39, HSC43, HSC44, HSC58, HSC59, HSC60, KATOIII, and OCUM2M) that were derived from gastric cancers were used. The treatment of the eight cell lines consisted of 5-aza-2Vdeoxycytidine (5Aza-dC, 1 Amol/L) for 24 hours, followed by addition of trichostatin A (TSA), to a final concentration of 1 Amol/L for a further 24 hours. Treatments with TSA alone and 5Aza-dC alone were also done by using the same amount of the drugs.
Microarray Analysis. For total RNA isolation, surgical specimens and cultured cells were mixed with IsoGen lysis buffer (Nippon Gene Co., Ltd., Toyama, Japan) at room temperature, extracted with chloroform, and precipitated with a glycogen carrier (20 Ag/AL) in isopropanol. The RNA pellet was washed with 70% ethanol prepared and dissolved in RNase-free water. We used human U95A version 2 arrays (Affymetrix, Santa Clara, CA) for analysis of mRNA expression levels corresponding to 12,626 transcripts. The procedures were conducted according to the protocols of the supplier. Briefly, 10 Ag of fragmented cRNA were hybridized to the microarrays in 200 AL of a hybridization cocktail at 45jC for 16 hours in a rotisserie oven set at 60 rpm. The arrays were then washed with a nonstringent wash buffer (6Â saline-sodium phosphate-EDTA) at 25jC, followed by a stringent wash buffer [100 mmol/L MES (pH 6.7), 0.1 mol/L NaCl, and 0.01% Tween 20] at 50jC, stained with streptavidin phycoerythrin (Molecular Probes, Eugene, OR), washed again with 6Â saline-sodium phosphate-EDTA, stained with biotinylated anti-streptavidin immunoglobulin G, followed by a second staining with streptavidin phycoerythrin and a third wash with 6Â salinesodium phosphate-EDTA. The arrays were scanned using a GeneArray scanner (Affymetrix) at 3-Am resolution, and the expression value (average difference) of each gene was calculated using GeneChip Analysis Suite version 4.0 software (Affymetrix). The mean of average difference values in each experiment was 1,000 to reliably compare variable multiple arrays. By use of human U95A version 2 arrays, we analyzed the eight treated and untreated gastric cancer cell lines twice and the 33 surgical specimens once.
To select reactivated genes in at least one cell line of the eight gastric cancer cell lines after treatment with 5Aza-dC and TSA, we compared the mean of average difference values of duplicated experiments between untreated cells and 24-hour-treated cells. More than 3-fold overexpressed genes were selected by Microsoft Excel. The dendrogram of the clustering analysis was generated using the programs Cluster and Treeview (18) . Reverse Transcription-PCR and cRNA Slot-Blot Analyses. First, we produced tens of micrograms of cRNA from 1 to 5 Ag total RNA prepared from the gastric cancer cell lines and the surgical specimen of gastric cancer by T7 transcription-mediated RNA amplification. Single stranded cDNAs were synthesized from 5 Ag cRNA by use of First-strand synthesis kit (Amersham Biosciences, Piscataway, NJ) with random hexamers. We carried out PCR in a volume of 25 AL containing 1Â Accuprime PCR buffer I (Invitrogen Corp., Carlsbad, CA), 0.5 Amol/L of each primer, and Accuprime Taq DNA polymerase (Invitrogen, Corpo, Carlsbad, CA). The thermal profile consisted of an initial denaturation at 95jC for 5 minutes followed by repetitions at 95jC for 1 minute, 56jC for 1 minute, and 72jC for 1 minute, with a final extension step at 72jC for 10 minutes. We amplified all of the genes from 50 ng of cDNA template with multiple cycle numbers (20-30 cycles) to determine the appropriate conditions for obtaining semiquantitative differences in expression levels. Primers for ELK1, R-RAS, RHOB, RHO6, and MSX2 were ELK1, 5V-ATGGGGCTTTTCAATAGGGG-3V and 5V-CCAG-GAGTCTTTTGAACCCA-3V; R-RAS, 5V-TCTGACTACGACCCCACTATTG-3V and 5V-AAGGGTGGGTATGTGATGTGTC-3V; RHOB , 5V-GCCTGCT GATCGTGTTCAGT-3V and 5V-GTCGTAGGCTTGGATGCGCA-3V; RHO6, 5V-CGCTCTGAACTCATCTCTTC-3V and 5V-GGACTTAGGTGAGAAGCATGTG-3V; and MSX2, 5V-CCTGTTGAGAGGAATTGATGG-3V and 5V-AAAGGTATACCG-GAGGGAGG-3V. Two micrograms of cRNA for each sample were incubated at 65C for 10 minutes and then blotted onto a nylon membrane, Hybond-N+ (Amersham). Probes were obtained by the above reverse transcription-PCR (RT-PCR) method and then labeled with [ 32 P]dCTP using a DNA labeling kit (Roche Diagnostics, Mannheim, Germany).
Methylation Analysis by Genomic Southern Blot. Five micrograms of genomic DNA from gastric cancer cell lines were digested to completion with HpaII or MspI. The restriction products were separated on 2% agarose gels and transferred to the nylon membranes. Two probes were obtained by genomic PCR using two primer sets, 5V-CTGGCTCATGGATTAGGAAT-3V and 5V-CATAATCATGAGCTCTGGCA-3V for probe 1, and 5V-ACCATCCAGTT-CATCCAGGT-3V and 5V-GGTGGAATCTCAAAGGTGCT-3V for probe 2.
Bisulfite Sequencing Analysis. A region containing site S1 (Fig. 4 ) was amplified from bisulfite-treated genomic DNA by PCR using two primer sets, 5V-TTTAAGTAGTTGAGATTATAGG-3V and 5V-CTCTCTTAAAACTA-AATAATCCC-3V for site S1 analysis. The PCR products were applied to the ABI 310 DNA analyzer (Applied Biosystems) using the above primers or nested primers.
Methylation-Specific PCR. Bisulfite-treated genomic DNA was amplified with either a methylation-specific or unmethylation-specific primer set at 40 cycles: at 95jC for 5 minutes followed by repetitions at 95jC for 45 seconds, 52jC (methylated) and 52jC (unmethylated) for 45 seconds, and 72jC for 1 minute, with a final extension step at 72jC for 10 minutes. The methylationspecific primers for site S1 were designed using 5V-TTTAAGTAGTTGAGATTA-TAGG-3Vas the forward primer and 5V-AAAAACTAAAAATCAAACGTAAAACCG-3V as the reverse primer. The unmethylation-specific primers for site S1 were designed using 5V-TTTAAGTAGTTGAGATTATAGG-3V as the forward primer and 5V-AAAAAAAACTAAAAATCAAACATAAAACCA-3V as the reverse primer.
RNAi Analysis. All siRNAs used for RNA interference of the R-RAS gene product were designed with an online siRNA design tool provided by Qiagen (http://www.qiagen.com/siRNA). Among the three siRNAs designed, which had no sequence identities with any other known genes including RAS family genes, two had a suppressive effect on R-RAS mRNA expression (data not shown). The target sequence used for subsequent analysis was ACACGAA-GATCTGCAGTGTGGAT. The negative control siRNA of which sequence has no known homology to mammalian genes was also purchased from Qiagen. HSC58 and HSC59 cells were inoculated in 24-well plates at a density of 3 Â 10 4 for each well. Twenty-four hours after inoculation, 76 pmol of siRNA were transfected into each well with RNAi Fect Transfection Reagent according to the instructions of the manufacturer (Qiagen). Fluoresceinlabeled negative control siRNA was used to monitor the efficiency of transfection. Transfected cells were trypsinized, stained with trypan blue, and counted viable cells with a hemocytometer at the indicated time.
Results
Genome-wide Screening of Genes Reactivated by Pharmacologic Unmasking of Methylation and Deacetylation. To identify genes induced by treatment with 5Aza-dC and TSA, we used eight gastric cancer cell lines, HSC39, HSC43, HSC44, HSC58, HSC59, HSC60, KATOIII, and OCUM2M. In previous studies, five tumor suppressor genes, including CDH1 (19), TIMP2 (20), CDKN2D (21), CDKN1C (22), and RUNX3 (23, 24) , have been reported to be silenced by DNA methylation in gastric cancer. First, as a preliminary test we showed the results of the above four genes, except for RUNX3, of a microarray analysis of less than 1,000 genes ( Fig. 1) . CDH1, TIMP2, CDKN2D, and CDKN1C were found to be induced in some of the eight gastric cancer cell lines by treatment with 5Aza-dC and TSA. We also confirmed the microarray data by RNA slot-blot analysis (data not shown). Next, all the RNA samples of untreated and treated cells were analyzed using microarrays containing 12,625 transcripts. In each cell line, f300 to 500 genes were found to be transcriptionally activated by the pharmacologic unmasking of methylation and deacetylation. Selection of Transcriptionally Activated Genes in Gastric Cancer by Cancer-Linked DNA Hypomethylation. To select genes showing abnormal expression in gastric cancer due to cancer-linked DNA hypomethylation, we compared expression profiles of 33 primary gastric cancers and 6 normal gastric mucosae. Of the 1,383 genes, 159 genes, which are suppressed in 6 normal tissues but expressed in at least one gastric cancer tissue, were selected (Table 1) . We showed the location of CpG islands near the first exon of the 159 genes in Table 1 . In concordance with a previous report (25) , four tumor antigen genes, MAGEA1, MAGEA4, MAGEA9, and CTAG1, were found. Gastric cancer mainly divides into two types, diffuse and intestinal. In a manner similar to a recent report for disruption of cell-type-specific methylation at the Maspin gene promoter in undifferentiated thyroid cancers (26), tumor suppressor genes (MSH5 and CDH1 encoding E-cadherin) or tumor suppressor gene-associated genes (BAP1 encoding BRCA1-associated protein-1, and three BCL2-associated protein genes, BIK, BBC3, and BAX) were also found to be activated by DNA hypermethylation. To investigate whether type-specific or subtypespecific DNA hypomethylation occurs, we did a hierarchical clustering analysis of the 159 genes in the 33 gastric cancer tissues including 16 diffuse type and 17 intestinal type. As shown in Fig. 2 , 7 of 17 intestinal type cancers (horizontal green bar) and 8 of 16 diffuse type cancers (horizontal red bar) were clustered. We also provided three representative gene clusters in an inset in Fig. 2 . The gene cluster of the diffuse type (vertical red bar) contains two known oncogenes, R-RAS and ARHB/RHOB, whereas that of the intestinal type (vertical green bar) contains an oncogene, ELK1.
In the gene list (Table 1) , we found six known oncogenes including a member of the ETS oncogene family, ELK1, an oncogene in WNT signaling, FRAT2, an oncogene amplified in gastric cancers, FGFR2, together with three oncogenes in the RAS/RHO family, R-RAS, RHOB, and RHO6. A Notch ligand, JAG1, and a target for the RAS signaling, MSX2, are also potential oncogene candidates. By RT-PCR analysis, we next investigated reactivation of the six oncogenes and the two oncogene candidates in eight gastric cancer cell lines by treatment with 5Aza-dC and/or TSA. As shown in Fig. 3A , five genes (ELK1, R-RAS, RHOB, RHO6, and MSX2) of the eight genes were reactivated by treatment with 5Aza-dC alone, TSA alone, and both 5Aza-dC and TSA. Although we have not done analyses to confirm reactivation, at least TK1, STAT1, RABGGTA, ABCC10, MMP10, CDC34, FZR1, and MAPK8IP1 are considered to be cancer-related genes. Among the five genes, we further analyzed the R-RAS gene because a critical promoter region has been previously reported (27) . First, we did RT-PCR analysis of R-RAS in 6 noncancerous tissues and 33 primary gastric cancers. R-RAS was suppressed in the 6 normal tissues but expressed in 18 (55%) of 33 gastric cancers (9 in 16 diffuse type cancers, 9 in 17 intestinal type cancers; Fig. 3B ). Figure 3 . A, RT-PCR analysis of four oncogenes, ELK1 , R-RAS , RHOB, and RHO6 , and one potential oncogene, MSX2 , in untreated and treated cells with 5Aza-dC and/or TSA. B, RT-PCR of R-RAS in 6 noncancerous tissues and 33 primary gastric cancer tissues. R-RAS is suppressed in the 6 normal tissues but expressed in 18 of 33 (55%) primary gastric cancers. C, RT-PCR of R-RAS in three laser-captured regions, the pit, isthmus/ neck, and gland, in the gastric mucosa. No R-RAS mRNA is detected in the three regions, whereas H-RAS mRNA is expressed in all of the three regions.
The gastric epithelium consists of tubular units of epithelial cells (28) . Each unit is divided into three successive regions from surface to base: pit, isthmus/neck, and gland. The isthmus or neck contains stem cells from which mature epithelial cells are derived and moved to the other two regions. Mucus-secreting pit cells migrate up from progenitor cells toward the gastric lumen. The neck cells migrate down toward the base of the gland where they give rise to pepsinogen-producing chief cells. To conclude that there is no R-RAS expression in all of the three regions in the gastric mucosa, we carried out RT-PCR analysis combined with a laser-captured microdissection procedure on the human gastric mucosa as described in our previous report (29) . With this procedure, no R-RAS mRNA was detected in the three regions whereas H-RAS mRNA was expressed in all of the three regions (Fig. 3C) . The expression of a pit cell marker, MUC5AC (30, 31), was significantly higher in the pit cell-enriched sample whereas a proliferating cell marker, PCNA, was detected preferentially in the neck cell-enriched sample. This indicates the procedure was appropriately done for our purpose. These results show that R-RAS is silenced in the gastric epithelium but activated in more than half of gastric cancers.
Aberrant Expression of R-RAS in
We found two CpG islands (GC content >50%, length >200 bp, and ratio of CpG to GpC >0.6) surrounding the first exon by searching with a UCSC Genome Browser (32, 33) . A schematic diagram of the structure of the 5V region of the R-RAS gene is shown in Fig. 4A . We first investigated the methylation status in the 5V region of R-RAS in eight gastric cancer cell lines by genomic Southern blot analysis with a methylation-sensitive enzyme, HpaII, and a resistant enzyme, MspI. Two probes for the Southern blots are shown in Fig. 4A , and results of Southern blot analysis with probe 2 and RNA slot-blot analysis for quantifying R-RAS mRNA levels in each cell line are shown in Fig. 4B . Southern blot analysis with probe 1 showed no correlation between the methylation status of the MspI/HapII sites and R-RAS expression levels (data not shown), whereas Southern blot analysis with probe 2 clearly showed two types of correlation ( Fig. 4A and B) . Four bands, termed B1-4, were detected in Southern blot analysis with probe 2. Increased R-RAS mRNA levels correlated with a shift from B3 to B1 in HSC39, KATOIII, Figure 4 . A, schematic diagram of the structure of the 5V region of the R-RAS gene. Genomic locus of the first exon was identified by UCSC Genome Browser and the 5V CpG island of R-RAS was detected by a CpG Island Searcher (42) . Two probes for genomic Southern blot analysis with HpaII and MspI are indicated (probe 1 and probe 2). MspI/HapI I sites including sites S1-4 and four bands, termed B1-4, which were detected in Southern blot analysis with probe 2 (B and C ), are also indicated. B, genomic Southern blot analysis with Hpa II and Msp I in eight gastric cancer cell lines using probe 2. H and M, blots with Hpa II and Msp I, respectively. Each result of RNA slot-blot analysis in eight gastric cancer cell lines is shown (bottom ). C, genomic Southern blot analysis with Hpa II and Msp I in two normal tissues and two primary gastric cancer tissues with R-RAS expression using probe 2. H and M, blots with Hpa II and MspI, respectively. Each result of RT-PCR in the above four samples is shown (bottom ). Two normal tissues (N1 and N2 ); two primary gastric cancer tissues [T1 (I-W5) and T2 (D-P(2)2s)]. D, methylation status of the MspI/HapII site S1 and its surrounding CpG sites in gastric cancer cell lines. R-RAS mRNA levels increased depending on the levels of demethylation on site S1 and its surrounding CpG sites in HSC39, KATOIII, HSC43 or OCUM2M, HSC60, and HSC58. E, methylation-specific PCR analysis on site S1 in normal tissues, gastric cancer cell lines, and primary gastric cancers. Two noncancerous tissues (N1 and N2); two primary gastric cancer tissues without R-RAS expression [T4 (I-P(1)11) and T5 (D-PS59)]; and three R-RAS-expressing cancer tissues [T1 (I-W5), T2 (D-P(2)2S), and T3 (I-W80)]. Demethylation on site S1 is found only in cancer cell lines and primary gastric cancers that express R-RAS mRNA. The PCR products in lanes U and M indicate the presence of unmethylated and methylated templates, respectively. HSC43 or OCUM2M, HSC60, and HSC58 (type I correlation in Fig. 4B ). Another correlation (type II) is that R-RAS mRNA levels increased depending on the shift from B2 to B4 in OCUM2M or HSC43, HSC59, and HSC44 (Fig. 4B) .
Thus, in gastric cancer cell lines, DNA demethylation for R-RAS activation occurred in a bidirectional manner or in two types; however, in primary gastric cancers, one of the two directions or the two types was only found by Southern blot analysis (data not shown). Representative data are shown in Fig. 4C . In two normal tissues (N1 and N2) and two primary gastric cancers with R-RAS mRNA expression (T1 and T2), R-RAS mRNA levels also increased depending mainly on the shift from B3 to B1 (Fig. 4C) . These data indicated that cancer-linked demethylation on the MspI/HapII site S1 mainly leads to abnormal expression of the R-RAS gene in gastric carcinogenesis.
By genomic bisulfite sequencing in eight gastric cancer cell lines, we confirmed the methylation status of the MspI/HapII site S1 and its surrounding CpG sites in gastric cancer. As shown in Fig. 4D , R-RAS mRNA levels increased depending on the levels of demethylation on site S1 and its surrounding CpG sites in HSC39, KATOIII, HSC43, HSC60, and HSC58.
We further did methylation-specific PCR using bisulfite-modified genomic DNAs in gastric cancer cell lines and primary gastric cancers. In the above five gastric cancer cell lines (HSC39, KATOIII, HSC43, HSC60, and HSC58), demethylation of site S1 was only found in HSC60 and HSC58 depending on the levels of R-RAS mRNA (Fig. 4E) . We also found a correlation between the demethylation status of site S1 and R-RAS expression was observed in primary gastric cancers. Representative data were shown in Fig. 4E . Two noncancerous tissues (N1 and N2) and two primary gastric cancer tissues [T4 (I-P(1)11) and T5 (D-PS59)] without R-RAS expression showed no demethylation, whereas three R-RASexpressing cancer tissues [T1 (I-W5), T2 (D-P(2)2S), and T3 (I-W80)] showed partial demethylation.
Suppression of R-RAS by RNAi Inhibited Cell Survival in R-RAS-Expressing Gastric Cancer Cells. By mutations at codons 38 or 87 analogous to positions 12 and 61 of H-RAS for its oncogenic activation, R-RAS has been reported to have oncogenic activity, although its activity is weaker than that of H-RAS or K-RAS (34). Therefore, we investigated whether oncogenic mutation of R-RAS occurs in gastric carcinogenesis. Direct sequencing analysis of genomic and cDNA fragments containing the above two sites showed no mutation in 22 gastric cancers with R-RAS mRNA expression (data not shown).
To clarify the biological meanings of aberrant expression of R-RAS mRNA in gastric cancer, we tried suppressing R-RAS in HSC58 cells with the highest level of R-RAS mRNA and HSC59 with no R-RAS mRNA by RNAi. The efficiencies of the siRNA introduction that were determined by use of a fluorescein-labeled negative control siRNA were 80% to 90% in HSC58 cells and 60% to 70% in HSC59 cells (data not shown). In R-RAS-expressing HSC58 cells, the introduction of R-RAStargeted siRNA significantly decreased the cell number that adhered to a plate at 48 hours after the introduction, but the control siRNA did not (Fig. 5B) , whereas no siRNA effect was observed in HSC59 cells (data not shown). Along with this effect in HSC58 cells, aggregated cells disappeared, and shrunken cells were frequently observed (Fig. 5C) . Because a decreased level of R-RAS mRNA was detected at 7.5 hours after siRNA transfection (Fig. 5A) , phenotypic alterations might be induced by some downstream events rather than a direct effect of decreased expression of R-RAS mRNA. In any case, these results suggest that R-RAS is essential for the survival of the gastric cancer cells that express R-RAS by DNA demethylation.
Discussion
In humans, the Ras family of small GTPases consists of nine closely related proteins and can be further divided into two subgroups in terms of structural similarity. The first of these contains the four classic p21 Ras proteins, H-RAS, N-RAS, K-RAS, and E-RAS that was previously recognized as a pseudogene of H-RAS but has now become a new member (35) . The other five subgroups consist of RAP, RAL, R-RAS, R-RAS2, and M-RAS. Each member has different effects on biological phenotypes.
The R-RAS gene was initially cloned as a ras-related gene (27) and showed interaction with the Bcl-2 gene product (36) . Owing to an actively mutated R-RAS inhibiting Bcl-2-mediated rescue of apoptosis, it is thought that R-RAS promotes apoptosis signaling pathway(s) (37) . On the other hand, as McCormick (38) pointed out, interaction between R-RAS and Bcl-2 might have a biological Figure 5 . A, real-time PCR analysis of R-RAS mRNA after siRNA transfection. Decreased R-RAS mRNA was detected at 7.5 hours after siRNA transfection, whereas no change of GAPDH mRNA level was observed even at 24 hours after the transfection. B, effect on cell growth and survival after siRNA transfection. The survived cell number clearly decreased at 48 hours after R-RAS siRNA transfection. C , morphologic changes of cells by siRNA transfection. Accompanied by decreasing cell number, aggregated cells disappeared and shrunken cells were observed at 48 hours after transfection of R-RAS siRNA.
function other than apoptosis because the Bcl-2 protein preferentially binds to the nucleotide-depleted form of R-RAS in vitro. Cell transformed by activated H-RAS can survive in the absence of serum whereas R-RAS-transformed cells seem to die by an apoptotic-like mechanism in response to the removal of the serum (39) . It has also been shown that R-RAS activates integrin-mediated and integrin-independent cell adhesion (40, 41) .
Suppression of R-RAS expression by RNA interference induced morphologic alteration and cell death (Fig. 5) . Because of the results of terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay showing that the proportion of apoptotic cells within the adherent cell population did not alter even after siRNA transfection (data not shown), cell death might arise immediately after cell detachment from the substrate by means of R-RAS interference by siRNA. Our results are consistent with the model for regulation of cell adhesion by R-RAS. The biological significance of the R-RAS function in tumor tissues should be analyzed in detail.
This study suggests that functional blocking of R-RAS itself and/or the R-RAS-signaling pathway has great potential for gastric cancer therapy. Moreover, methylation-specific PCR analysis of the R-RAS gene could become a conventional tool for identifying target patients for any new drug that may be developed in the near future.
In the same manner, the gene list containing 159 genes also provides many candidates for cancer-related genes that are transcriptionally activated by DNA hypomethylation in human cancers. Further identification of such genes may provide insight into tumor biology and provide novel diagnostic and therapeutic targets.
